<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">asurgery</journal-id><journal-title-group><journal-title xml:lang="ru">Амбулаторная хирургия</journal-title><trans-title-group xml:lang="en"><trans-title>Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2712-8741</issn><issn pub-type="epub">2782-2591</issn><publisher><publisher-name>ООО «ГРУППА РЕМЕДИУМ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">asurgery-98</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБМЕН ОПЫТОМ | ПРАКТИКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXCHANGE OF EXPERIENCE  |  PRACTICE</subject></subj-group></article-categories><title-group><article-title>Опыт амбулаторного мультидисциплинарного ведения пациентов с венозными тромбозами</article-title><trans-title-group xml:lang="en"><trans-title>Experience of outpatient multidisciplinary management of patients with venous thrombosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бурлева</surname><given-names>Е. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Burleva</surname><given-names>E. P.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бражников</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Brazhnikov</surname><given-names>A. Yu.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белова</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Belova</surname><given-names>A. D.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Уральский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Уральский государственный медицинский университет; Городская клиническая больница №2</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Hospital No 2</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2017</year></pub-date><volume>0</volume><issue>3-4</issue><fpage>105</fpage><lpage>111</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бурлева Е.П., Бражников А.Ю., Белова А.Д., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Бурлева Е.П., Бражников А.Ю., Белова А.Д.</copyright-holder><copyright-holder xml:lang="en">Burleva E.P., Brazhnikov A.Y., Belova A.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.a-surgeon.ru/jour/article/view/98">https://www.a-surgeon.ru/jour/article/view/98</self-uri><abstract><p>Целью работы было обобщение опыта амбулаторного ведения пациентов с тромбозами глубоких вен (ТГВ) нижних конечностей мультидисциплинарной врачебной командой. Материалы и методы. Проанализированы три аспекта деятельности: 1. 5-летнее амбулаторное ведение 190 пациентов с ТГВ (1 гр. - 134, стартовая антикоагуляционная терапия (АКТ) в условиях стационара, 2 гр. - 56, стартовая АКТ в амбулаторных условиях). 2. Поиск генетических тромбофилий (n = 18). 3. Амбулаторное ведение пациентов с применением риварок-сабана (n = 27). Представлен клинико-диагностический алгоритм ведения пациентов с ТГВ. Результаты. Выявлено, что стартовая АКТ в условиях стационара и в амбулаторных условиях одинаково эффективна и безопасна, позволяет получить гипокоагуляционный и антитромботический эффекты, достичь реканализации венозного русла различной степени (1 гр. - 85,4%, 2 гр. - 78%) при незначительном числе малых геморрагических осложнений (2,2 и 1,8%). В 5-летнем периоде наблюдения выявлено, что процессы ре-канализации зависят от распространенности поражения венозного русла и уровня верхней границы исходного тромбоза, приверженность пациентов к АКТ зарегистрирована в 92,1% случаев, рецидив ТГВ - 2,8% (4 эпизода). В группе пациентов, обследованных на генетическую тромбо-филию, зарегистрированы мутации: FII R506Q 1691 - 33,3%, FII G2021A - 5,6%, FII + FV - 11,1%. Эпизоды ТЭЛА осложнили течение ТГВ в 26,3%. У 27 пациентов, лечившихся с помощью ривароксабана, достигнут клинический успех в виде уменьшения болевого синдрома и отека. При УЗАС во всех случаях выявлены признаки хорошей реканализации, рецидивы ТГВ и ТЭЛА не зарегистрированы. Заключение. Применение алгоритма амбулаторного мультидисциплинарного ведения пациентов с ТГВ командой специалистов позволяет выявить возможные причины тромбоза, добиться эффективной терапии с использованием современных протоколов и препаратов, решить вопрос о профилактике рецидивов ТГВ, выявить генетическую предрасположенность и устранить факторы тромбофильного риска.</p></abstract><trans-abstract xml:lang="en"><p>The study objective was to generalize the experience of outpatient management of patients with deep vein thrombosis (DVT) of the lower extremities by a multidisciplinary medical team. Materials and methods. Three aspects of activity were analysed: 1. 5-year outpatient management of 190 patients with DVT (arm 1 -134, initial anticoagulation therapy (ACT) in hospital settings, arm 2 -56, initial ACT in outpatient settings). 2. Identification of genetic thrombophilia (n = 18), 3. Outpatient management of patients using rivaroxaban (n = 27). The article presents the clinico-diagnostic algorithm for managing patients with DVT. Results. It was revealed that the initial ACT conducted both in hospital and outpatient settings was equally efficient and safe, made it possible to obtain hypocoagulation and antithrombotic effects, achieve different degrees of recanalization of the venous bed (arm 1 - 85.4%, arm 2 - 78%) with insignificant number of small hemorrhagic complications (2.2% and 1.8%). During a 5-year period after thrombosis, the recanalization processes depend on the lesion site of the venous bed and the level of the upper border of the initial thrombosis, the adherence of patients to ACT was reported in 92.1% of cases, relapse of DVT amounted to 2.8% (4 episodes). In the group of patients examined for the genetic thrombophilia following mutations have been registered: (FII G2021A - 5.6%), Leiden mutation (FV R506Q 1691 - 42.1%), PE development accounted for 26.3%. A clinical success was achieved in 27 patients treated with Rivaroxaban in the form of a reduction in pain syndrome and edema. In all cases, US-angioscanning showed signs of good recanalization, relapses of DVT and PE were not recorded. Conclusion. The application by a team of specialists of the outpatient multidisciplinary management algorithm for patients with DVT makes it possible to identify possible causes of thrombosis, achieve effective therapy using modern protocols and drugs, solve the problem of preventing DVT relapses, identify genetic predisposition and eliminate the thrombophilic risk factors.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>тромбозы глубоких вен</kwd><kwd>мультидисциплинарная команда специалистов</kwd><kwd>генетические тромбофилии</kwd><kwd>амбулаторное лечение</kwd><kwd>ривароксабан</kwd><kwd>deep vein thrombosis</kwd><kwd>multidisciplinary team of specialists</kwd><kwd>genetic thrombophilia</kwd><kwd>outpatient management</kwd><kwd>Rivaroxaban</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Duru S, Kelesoglu A, Ardic S. Clinical update on pulmonary embolism. Arch MedSci, 2014, 10: 557-565.</mixed-citation><mixed-citation xml:lang="en">Duru S, Kelesoglu A, Ardic S. Clinical update on pulmonary embolism. Arch MedSci, 2014, 10: 557-565.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Карпенко А. А., Шилова А. Н. Современные данные о патоге незе венозного тромбоза. Тромбоз, гемостаз и реология, 2016, 2(66): 12-18.</mixed-citation><mixed-citation xml:lang="en">Карпенко А. А., Шилова А. Н. Современные данные о патоге незе венозного тромбоза. Тромбоз, гемостаз и реология, 2016, 2(66): 12-18.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev., 2009, 23(5): 225-229.</mixed-citation><mixed-citation xml:lang="en">Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev., 2009, 23(5): 225-229.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Российские клинические рекомендации по диагностики, лече нию и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология, 2015, 9(4): 52.</mixed-citation><mixed-citation xml:lang="en">Российские клинические рекомендации по диагностики, лече нию и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология, 2015, 9(4): 52.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Барышева В.О. Результаты применения фармакогенетического тестирования для персонализации антикоагулянтной и анти-агрегантной терапии. Тромбоз, гемостаз и реология, 2015, 4(64): 31-35.</mixed-citation><mixed-citation xml:lang="en">Барышева В.О. Результаты применения фармакогенетического тестирования для персонализации антикоагулянтной и анти-агрегантной терапии. Тромбоз, гемостаз и реология, 2015, 4(64): 31-35.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Raskob GE, Silverstein R, Bratzler DW et al. Surveillance for Deep Vein Thrombosis and Pulmonary Embolism. Recommendations from a National Workshop. AJPM, 2010, 38(4), Suppl.: S502-S509.</mixed-citation><mixed-citation xml:lang="en">Raskob GE, Silverstein R, Bratzler DW et al. Surveillance for Deep Vein Thrombosis and Pulmonary Embolism. Recommendations from a National Workshop. AJPM, 2010, 38(4), Suppl.: S502-S509.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Samama MM, Guinet C. Laboratory assessment of new anticoagu lants. Clinical Chemistry and Laboratory Medicine, 2011, 49(5): 761-772.</mixed-citation><mixed-citation xml:lang="en">Samama MM, Guinet C. Laboratory assessment of new anticoagu lants. Clinical Chemistry and Laboratory Medicine, 2011, 49(5): 761-772.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Рогозина А.С., Воробьева Н.А. Первый опыт работы антикоагулянтной клиники Архангельска. Экология человека, 2012, 2: 59-64.</mixed-citation><mixed-citation xml:lang="en">Рогозина А.С., Воробьева Н.А. Первый опыт работы антикоагулянтной клиники Архангельска. Экология человека, 2012, 2: 59-64.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Pengo V, Pegoraro C, Cucchini U et al. Worldwide Management of Oral Anticoagulant Therapy: the ISAM Study. J. Thrombosis and Thrombolysis, 2006, 21(1): 73-77.</mixed-citation><mixed-citation xml:lang="en">Pengo V, Pegoraro C, Cucchini U et al. Worldwide Management of Oral Anticoagulant Therapy: the ISAM Study. J. Thrombosis and Thrombolysis, 2006, 21(1): 73-77.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kelly M, John G. Comparison of Two Different Models of Anticoagulation Management Services with Usual Medical Care. Pharmacotherapy, 2010, 30(4): 330-338.</mixed-citation><mixed-citation xml:lang="en">Kelly M, John G. Comparison of Two Different Models of Anticoagulation Management Services with Usual Medical Care. Pharmacotherapy, 2010, 30(4): 330-338.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Heneghan C, Ward A, Perera R et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet, 2012, 28, 379(9813): 322-334.</mixed-citation><mixed-citation xml:lang="en">Heneghan C, Ward A, Perera R et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet, 2012, 28, 379(9813): 322-334.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Janzic A, Kos M. Influence of novel oral anticoagulants on anticoagulation care management. Acta Pharm, 2017, 67: 397-406.</mixed-citation><mixed-citation xml:lang="en">Janzic A, Kos M. Influence of novel oral anticoagulants on anticoagulation care management. Acta Pharm, 2017, 67: 397-406.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Леонтьев С.Г., Золотухин И.А., Селиверстов Е.И. и др. Амбулаторное лечение тромбозов глубоких вен нижних конечностей. Флебология, 2009, 3(4): 41-44.</mixed-citation><mixed-citation xml:lang="en">Леонтьев С.Г., Золотухин И.А., Селиверстов Е.И. и др. Амбулаторное лечение тромбозов глубоких вен нижних конечностей. Флебология, 2009, 3(4): 41-44.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Белова А.Д., Бурлева Е.П., Беленцов С.М. Сравнительная оценка стартового амбулаторного и стационарного лечения пациентов с тромбозом глубоких вен нижних конечностей. Новости хирургии, 2011, 19(6): 64-68.</mixed-citation><mixed-citation xml:lang="en">Белова А.Д., Бурлева Е.П., Беленцов С.М. Сравнительная оценка стартового амбулаторного и стационарного лечения пациентов с тромбозом глубоких вен нижних конечностей. Новости хирургии, 2011, 19(6): 64-68.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lozano F, Trujillo-Santos J, Barr4n M et al. Home versus in-hospi-tal treatment of outpatients with acute deep venous thrombosis of the lower limbs. J. Vasc. Surg., 2014 , 59(5): 1362-1367.</mixed-citation><mixed-citation xml:lang="en">Lozano F, Trujillo-Santos J, Barr4n M et al. Home versus in-hospi-tal treatment of outpatients with acute deep venous thrombosis of the lower limbs. J. Vasc. Surg., 2014 , 59(5): 1362-1367.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Baglin T. Management of thrombophilia: who to screen? Pathophysiol. Haemost. Thromb., 2003/2004, 33: 401-404.</mixed-citation><mixed-citation xml:lang="en">Baglin T. Management of thrombophilia: who to screen? Pathophysiol. Haemost. Thromb., 2003/2004, 33: 401-404.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wu O, Robertson L, Twaddle S et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol. Assess., 2006, 10(11): 1-110.</mixed-citation><mixed-citation xml:lang="en">Wu O, Robertson L, Twaddle S et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol. Assess., 2006, 10(11): 1-110.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Jeffrey I Weitz MD, Anthonie WA et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N. Engl. J. Med., 2017, 376: 1211-1222.</mixed-citation><mixed-citation xml:lang="en">Jeffrey I Weitz MD, Anthonie WA et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N. Engl. J. Med., 2017, 376: 1211-1222.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Andreozzi GM, Bignamini AA, Davi G et al. Sulodexide for prevention of recurrent venous thromboembolism. Circulation, 2015, 132(20): 1891-1897.</mixed-citation><mixed-citation xml:lang="en">Andreozzi GM, Bignamini AA, Davi G et al. Sulodexide for prevention of recurrent venous thromboembolism. Circulation, 2015, 132(20): 1891-1897.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
